- Home
- GMAB vs TECK Comparison
GMAB vs TECK Comparison
Compare GMAB & TECK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- TECK
- Stock Information
- Founded
- GMAB 1999
- TECK 1913
- Country
- GMAB Denmark
- TECK Canada
- Employees
- GMAB N/A
- TECK N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- TECK
- Sector
- GMAB Health Care
- TECK
- Exchange
- GMAB Nasdaq
- TECK Nasdaq
- Market Cap
- GMAB 17.4B
- TECK 20.7B
- IPO Year
- GMAB N/A
- TECK N/A
- Fundamental
- Price
- GMAB $31.32
- TECK $42.23
- Analyst Decision
- GMAB Strong Buy
- TECK Buy
- Analyst Count
- GMAB 6
- TECK 7
- Target Price
- GMAB $40.40
- TECK $54.00
- AVG Volume (30 Days)
- GMAB 1.8M
- TECK 3.6M
- Earning Date
- GMAB 11-06-2025
- TECK 10-22-2025
- Dividend Yield
- GMAB N/A
- TECK 0.85%
- EPS Growth
- GMAB 132.41
- TECK 166.96
- EPS
- GMAB 25.10
- TECK 1.80
- Revenue
- GMAB $3,845,670,022.00
- TECK $7,526,796,802.00
- Revenue This Year
- GMAB $24.92
- TECK $16.97
- Revenue Next Year
- GMAB $15.97
- TECK $5.95
- P/E Ratio
- GMAB $1.25
- TECK $23.44
- Revenue Growth
- GMAB 29.57
- TECK 29.08
- 52 Week Low
- GMAB $17.24
- TECK $28.32
- 52 Week High
- GMAB $33.65
- TECK $48.47
- Technical
- Relative Strength Index (RSI)
- GMAB 63.22
- TECK 53.32
- Support Level
- GMAB $29.98
- TECK $38.00
- Resistance Level
- GMAB $30.82
- TECK $41.20
- Average True Range (ATR)
- GMAB 0.65
- TECK 1.43
- MACD
- GMAB 0.15
- TECK -0.09
- Stochastic Oscillator
- GMAB 94.93
- TECK 71.61
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About TECK Teck Resources Ltd
Teck is a base metals miner with copper and zinc operations in Canada, the United States, Chile, and Peru. After selling its metallurgical coal business, copper is now its major commodity by EBITDA contribution, followed by zinc. Teck is a top-three zinc miner. Its major new copper mine in Chile at the majority-owned Quebrada Blanca 2, in partnership with Sumitomo, will drive an increase in Teck's attributable copper production by roughly 75%. Along with a number of additional copper growth options, Teck's strategy is to rebalance its portfolio to low-carbon metals such as copper. It sold its oil sands business in early 2023 and its coal business in mid-2024. In September 2025, it agreed to merge with Anglo American.